AbbVie is a large pharmaceutical company that develops and sells prescription drugs, primarily in immunology, oncology, and aesthetics. Key products include Skyrizi and Rinvoq (autoimmune conditions), Imbruvica and Venclexta (blood cancers), and Botox (both cosmetic and therapeutic uses). Revenue comes from drug sales to patients via hospitals, specialty pharmacies, and insurers. Humira, historically its biggest product, has faced biosimilar competition since 2023, making Skyrizi and Rinvoq increasingly central to growth. Recent acquisitions have added neuroscience and oncology pipeline assets.
Employees57,000IPOSep 4, 2014SIC5122HQ1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
to
Financials (EUR)
Profitability
Metric
Current
Margins
Gross Margin
71.5%
Operating Margin
33.9%
EBITDA Margin
30.3%
Net Margin
9.8%
OCF Margin
30.2%
FCF Margin
28.2%
Returns on Capital
ROE
—
ROA
4.7%
ROIC
14.1%
ROCE
12.4%
ROC (Greenblatt)
208.3%
3Y ROIIC
355.4%
Consistency
Years Profitable / 10Y
10
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
70.27
Forward P/E
17.66
P/E ex-NRI
22.89
Shiller P/E (CAPE)
51.66
Cash Flow Multiples
P/FCF
24.22
P/OCF
22.61
P/Owner Earnings
47.05
FCF Yield
4.10%
Enterprise Value Multiples
EV / EBIT
43.75
EV / Forward EBIT
19.75
EV / EBITDA
26.08
EV / Forward EBITDA
15.51
EV / Revenue
7.90
EV / Forward Revenue
7.45
Asset / Sales
P/S
6.85
P/B
—
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
2.71%
Forward Dividend Yield
2.81%
3Y Dividend Growth
5.2%
Payout Ratio
0.62
5Y Yield on Cost
3.73%
Buybacks & Dilution
3Y Buyback Ratio
0.00%
Combined
Shareholder Yield
2.98%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
−11.93
Gross Debt / EBITDA
3.64
Cash / Debt
0.09
Equity / Assets
−0.04
Coverage
Interest Coverage
7.49
Short-Term Liquidity
Current Ratio
0.81
Quick Ratio
0.69
Cash Ratio
0.16
Composite Scores
Piotroski F-Score
8
Altman Z-Score
2.38
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2026-07-15
$1.73
2026-08-14
2026-04-15
$1.73
2026-05-15
2026-01-16
$1.73
2026-02-17
2025-10-15
$1.64
2025-11-14
2025-07-15
$1.64
2025-08-15
2025-04-15
$1.64
2025-05-15
2025-01-15
$1.64
2025-02-14
2024-10-15
$1.55
2024-11-15
2024-07-15
$1.55
2024-08-15
2024-04-12
$1.55
2024-05-15
10 of 48
View allDate
Transcript
Type
No transcripts found.
5-Step DuPont Analysis
ROE %
-205.12%
×
×
Net Margin %
9.84%
×
×
Operating Margin %
33.96%
Operating Income
€18.80B
÷
Revenue
€55.36B
×
Tax Burden
0.7264
Net Income
€5.45B
÷
Pretax Income
€7.50B
×
Interest Burden
0.3989
Pretax Income
€7.50B
÷
Operating Income
€18.80B
×
Asset Turnover
0.47
÷
Revenue
€55.36B
÷
Average Total Assets
€118.11B
Begin Total Assets
€118.94B
End Total Assets
€117.28B
×
Equity Multiplier
-44.48
÷
Avg Total Assets
€118.11B
÷
Avg Stockholders Equity
−€2.66B
Begin Equity
−€159M
End Equity
−€5.15B